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Aims Chronic obstructive pulmonary disease (COPD) is an important comorbidity in heart failure (HF) with
reduced ejection fraction (HFrEF), associated with worse outcomes and often suboptimal treatment because
of under-prescription of beta-blockers. Consequently, additional effective therapies are especially relevant in
patients with COPD. The aim of this study was to examine outcomes related to COPD in a post hoc analysis
of the Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial.
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Methods
and results
We examined whether the effects of dapagliflozin in DAPA-HF were modified by COPD status. The primary
outcome was the composite of an episode of worsening HF or cardiovascular death. Overall, 585 (12.3%) of the
4744 patients randomized had a history of COPD. Patients with COPD were more likely to be older men with a
history of smoking, worse renal function, and higher baseline N-terminal pro B-type natriuretic peptide, and less
likely to be treated with a beta-blocker or mineralocorticoid receptor antagonist. The incidence of the primary
outcome was higher in patients with COPD than in those without [18.9 (95% confidence interval 16.0–22.2)
vs. 13.0 (12.1–14.0) per 100 person-years; hazard ratio (HR) for COPD vs. no COPD 1.44 (1.21–1.72);
P< 0.001]. The effect of dapagliflozin, compared with placebo, on the primary outcome, was consistent in
patients with [HR 0.67 (95% confidence interval 0.48–0.93)] and without COPD [0.76 (0.65–0.87); interaction
P-value 0.47].
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Conclusions In DAPA-HF, one in eight patients with HFrEF had concomitant COPD. Participants with COPD had a higher
risk of the primary outcome. The benefit of dapagliflozin on all pre-specified outcomes was consistent in
patients with and without COPD.
Clinical Trial Registration: ClinicalTrials.gov ID NCT03036124.
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Introduction
Chronic obstructive pulmonary disease (COPD) has a higher
prevalence in patients with heart failure (HF) than in the gen-
eral population.1–3 While this most likely reflects the common
aetiological role of smoking in each condition, inflammation and
oxidative stress have also been postulated to play a role.1–3 COPD
is important in HF for two principal reasons. First, HF patients
with COPD have worse outcomes, including higher mortality,
than HF patients without COPD.1–6 Second, concomitant COPD
has implications for the use of specific HF therapies.1–3,7 Physi-
cians may be reluctant to use beta-blockers in HF patients with
COPD, because of their bronchospastic effects, even though these
drugs are lifesaving in patients with HF with reduced ejection
fraction (HFrEF). Although still indicated and generally well tol-
erated in most patients with COPD, even in high-risk settings,
new evidence also shows that beta-blockers can increase the
risk of respiratory hospitalization in patients with more severe
COPD.8,9 It is also advised that hydralazine and isosorbide dini-
trate are avoided in patients with COPD as this combination
may lead to worsening gas exchange and hypoxaemia.7 Similarly,
hypokalaemia induced by beta-agonists, glucocorticoids and xan-
thine derivatives may make digoxin use more hazardous in patients
with COPD, compared to those without and increase risk of
arrhythmias.7,10,11
Consequently, there is a need for new therapies, both in addi-
tion to conventional treatment and, occasionally, as an alterna-
tive due to non-tolerance of standard pharmacotherapies, in these
high-risk individuals with both HFrEF and COPD. Recently, specific
sodium–glucose co-transporter 2 inhibitors have demonstrated
reduction in mortality and risk of HF hospitalization in patients
with HFrEF.12–14 In this post hoc analysis, we examined the effects
of dapagliflozin in HFrEF patients with and without COPD enrolled
in the Dapagliflozin And Prevention of Adverse-outcomes in Heart
Failure (DAPA-HF) trial.12,15,16
Methods
DAPA-HF was a randomized, double-blind, placebo-controlled,
event-driven trial in HFrEF patients.12,15,16 Efficacy and safety of
dapagliflozin 10 mg once daily, plus standard care, was compared
with matching placebo. The design, baseline characteristics, and
primary results are published.12,15,16 The Ethics Committee of the
410 participating institutions (20 countries) approved the protocol,
and all patients gave written informed consent. The investiga-






































































Enrolment criteria included HF with left ventricular ejection fraction
(LVEF) ≤40%, age ≥18 years, New York Heart Association (NYHA)
functional class II–IV, elevated N-terminal pro B-type natriuretic
peptide (NT-proBNP), and optimal pharmacological and device ther-
apy. The protocol required guideline-recommended medications,
including beta-blocker, unless contraindicated/not tolerated. Key
exclusion criteria included: symptomatic hypotension/systolic blood
pressure <95 mmHg, estimated glomerular filtration rate (eGFR)
<30 mL/min/1.73 m2(or rapidly declining renal function), and type 1
diabetes mellitus. No exclusions were related to COPD or asthma.
Identification of chronic obstructive
pulmonary disease and study follow-up
An investigator-reported history of COPD was identified from a check
box on the case report form. No specific instructions were given in
relation to diagnosis of COPD. Investigators reported diagnosis of
asthma similarly. There were no respiratory disease or respiratory
treatment-related exclusions, although investigators were asked to
exclude patients with another condition likely to lead to life expectancy
of <2 years. After randomization, follow-up visits occurred at 14, 60,
120, 240, 360 days and every 4 months thereafter.
Study outcomes
The primary trial outcome was the composite of worsening HF (HF
hospitalization or urgent visit for HF requiring intravenous therapy)
or cardiovascular (CV) death, whichever occurred first. Pre-specified
secondary endpoints included HF hospitalization or CV death; HF
hospitalizations (first and recurrent) and CV deaths; change from
baseline to 8 months in Kansas City Cardiomyopathy Questionnaire
total symptom score (KCCQ-TSS)18; incidence of worsening renal
function and all-cause death (because of few renal events overall, this
endpoint was not examined in the present analysis). In addition to the
pre-specified outcomes, we also analysed: (i) KCCQ overall summary
score (KCCQ-OSS) and KCCQ clinical summary score (KCCQ-CSS),
and (ii) non-CV deaths, in view of the potential impact of COPD
on quality of life and deaths from respiratory causes and infection.
Pre-specified safety analyses included any serious adverse event (AE),
AEs related study drug discontinuation, AEs of interest and laboratory
findings of note.
Statistical analysis
The primary analysis examined patients with an investigator-reported
history of COPD, including a small number with concurrent asthma;
patients with asthma alone were examined in supplementary analyses
(online supplementary material).
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Baseline characteristics were summarized as means (standard devi-
ations), median (interquartile ranges), or percentages. Time-to-event
data were evaluated using Kaplan–Meier estimates and Cox
proportional-hazards models, stratified by diabetes status, and adjusted
for history of HF hospitalization (except for non-CV and all-cause
death) and treatment-group assignment. We used a semiparametric
proportional-rates model to analyse total (including recurrent) events,
as previously described. We also adjusted the effect of COPD status
in two additional models: Model 1 included age, sex, region, systolic
blood pressure, history of atrial fibrillation, NYHA class III/IV, LVEF, log
NT-proBNP, eGFR and smoking status. Model 2 had additional adjust-
ment for baseline beta-blocker and mineralocorticoid receptor antag-
onist (MRA) prescription. We analysed mean change in KCCQ-TSS
from baseline to 8 months. Safety analyses were performed in ran-
domized patients who had received at least one dose of dapagliflozin
or placebo (8 of 4744 patients excluded). Interaction between COPD
status and treatment effect on the occurrence of the pre-specified
safety outcomes was tested in a logistic regression model with an
interaction term between baseline COPD status and treatment.
All analyses were conducted using Stata version 16.1 (Stata Corp.,
College Station, TX, USA). A P-value <0.05 was considered statistically
significant.
Results
Overall, 585 (12.3%) of 4744 patients randomized had COPD, 299
(12.6%) in the dapagliflozin group and 286 (12.1%) in the placebo
group.
Patient characteristics
Table 1 shows baseline characteristics of those with and with-
out COPD. Patients with COPD were more often male, older
and current or ex-smokers, compared to those without COPD.
Patients with COPD had lower (worse) median KCCQ-TSS score
and a worse NYHA functional class distribution than those with-
out COPD. A similar proportion of patients with and without
COPD had a history of coronary heart disease, but patients with
COPD had worse renal function, a higher prevalence of atrial fibril-
lation and higher median NT-proBNP than those without COPD.
Patients with COPD were only slightly less likely to be treated with
beta-blocker but were also less likely to be prescribed MRA. COPD
patients treated with beta-blocker were less likely to be taking a
non-selective antagonist and more likely to have been prescribed
beta-1 adrenoceptor selective agent than those without COPD.
Among patients with COPD, 213 (36.4%) were treated with
inhaled beta-agonist, 138 (23.6%) with muscarinic antagonist, and
71 (12.1%) with a corticosteroid (online supplementary Table S1).
Baseline characteristics were similar in patients with and without
COPD randomized to placebo and dapagliflozin (online supplemen-
tary Table S1).
Of the 585 patients with COPD, investigators also reported a
diagnosis of asthma in 56 and an additional 133 patients had an
investigator-reported diagnosis of asthma only (online supplemen-
tary Tables S2 and S3). Patients with asthma only compared to
COPD were distinct in several respects, e.g. younger, more likely



















































































.. also some similarities between patients with COPD and asthma
(as compared to patients without COPD/asthma), including worse
KCCQ score, lower eGFR and higher prevalence of atrial fibrilla-
tion. Although beta-blocker use was high (91.0%) in patients with
asthma only, it was lower than in any other group. Conversely, the
use of corticosteroids was highest in patients with asthma, com-
pared with COPD only.
Hospitalization and mortality outcomes
in patients with and without chronic
obstructive pulmonary disease
Primary outcome
The incidence rate (per 100 person-years) of the primary com-
posite outcome was higher in patients with COPD than in those
without [18.9, 95% confidence interval (CI) 16.0–22.2 vs. 13.0,
95% CI 12.1–14.0] (Table 2, Figure 1, Graphical Abstract and online
supplementary Figure S1). Elevated risk persisted after adjustment
for other prognostic variables and use of a beta-blocker or MRA.
The elevation of risk was somewhat higher when recurrent events
were included (Table 2). Figure 2 shows the excess risk associated
with COPD was similar to the risk associated with chronic kidney
disease and diabetes, and greater than the other comorbidities
examined.
Worsening heart failure events
Adjusted risk of a worsening HF event was also significantly higher
in patients with COPD, compared to those without.
Mortality
By contrast, the crude incidence of CV death was only slightly
higher in patients with COPD and the adjusted risk was not signif-
icantly elevated. However, unadjusted and adjusted risk of death
from any cause was higher in patients with COPD, because of a
substantially elevated (twofold) risk of non-CV death (Table 2). The
excess of non-CV causes of death in patients with COPD were
those attributed to infection and ‘other’ (online supplementary
Figure S2).
Mortality and hospitalization rates for patients with asthma only
(compared with COPD only) are shown in online supplementary
Figure S3. Due to the small number of individuals in the latter
group (n = 133), formal statistical testing was not done although
the rate of HF hospitalization seemed to be almost as high in
patients with COPD (but mortality was similar to patients without
COPD or asthma).
Symptoms and quality of life assessed
using the Kansas City Cardiomyopathy
Questionnaire in patients with and
without chronic obstructive pulmonary
disease
Figure 3A shows the impact of COPD on self-reported health
status. All but one of the KCCQ domains were significantly worse
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Age (years) 66.3 ±10.9 66.0 ±11.0 69.1 ± 9.4 <0.001
Women 1109 (23.4) 1002 (24.1) 107 (18.3) 0.002
Region <0.001
Asia/Pacific 1096 (23.1) 1010 (24.3) 86 (14.7)
Europe 2154 (45.4) 1858 (44.7) 296 (50.6)
North America 677 (14.3) 541 (13.0) 136 (23.2)
South America 817 (17.2) 750 (18.0) 67 (11.5)
Race <0.001
White 3333 (70.3) 2864 (68.9) 469 (80.2)
Black 226 (4.8) 202 (4.9) 24 (4.1)
Asian 1116 (23.5) 1028 (24.7) 88 (15.0)
Other 69 (1.5) 65 (1.6) 4 (0.7)
HR (bpm) 71.5 ±11.7 71.4 ±11.7 72.0 ±11.4 0.24
SBP (mmHg) 121.8 ±16.3 121.5 ±16.3 123.8 ±16.6 0.001
DBP (mmHg) 73.5 ±10.5 73.5 ±10.5 73.2 ±10.2 0.42
BMI (kg/m2) 28.2 ± 6.0 28.1 ± 5.9 28.3 ± 6.4 0.50
Hypertension 3523 (74.3) 3049 (73.3) 474 (81.0) <0.001
Diabetes 2139 (45.1) 1861 (44.7) 278 (47.5) 0.21
Myocardial infarction 2092 (44.1) 1825 (43.9) 267 (45.6) 0.42
Atrial fibrillation 1818 (38.3) 1557 (37.4) 261 (44.6) <0.001
Stroke 466 (9.8) 405 (9.7) 61 (10.4) 0.60
HF aetiology 0.49
Ischaemic 2674 (56.4) 2331 (56.0) 343 (58.6)
Non-ischaemic 1687 (35.6) 1489 (35.8) 198 (33.8)
Unknown 383 (8.1) 339 (8.2) 44 (7.5)
Previous HF hospitalization 2251 (47.4) 1951 (46.9) 300 (51.3) 0.047
Smoking status <0.001
Never 1959 (41.3) 1854 (44.6) 105 (18.0)
Former 2092 (44.1) 1770 (42.6) 322 (55.0)
Current 693 (14.6) 535 (12.9) 158 (27.0)
KCCQ-TSS 77 (58–92) 79 (60–93) 71 (53–85) <0.001
NYHA class III/IV 1541 (32.5) 1292 (31.1) 249 (42.6) <0.001
LVEF (%) 31.1 ± 6.8 31.0 ± 6.8 31.6 ± 6.8 0.036
NT-proBNP (pg/mL) 1437 (857–2650) 1418 (850–2616) 1574 (893–2807) 0.021
No AF 1254 (744–2341) 1237 (739–2270) 1493 (808–2845) 0.002
With AF 1792 (1107–3056) 1798 (1114–3097) 1704 (1044–2765) 0.18
eGFR (mL/min/1.73 m2) 65.8 ±19.4 66.1 ±19.4 63.4 ±19.4 0.001
eGFR <60 mL/min/1.73 m2 1926 (40.6) 1652 (39.7) 274 (46.9) <0.001
Creatinine (μmol/L) 104.4 ± 30.4 104.0 ± 30.0 107.6 ± 32.8 0.007
Haemoglobin (g/L) 135.5 ±16.2 135.5 ±16.2 135.8 ±16.4 0.63
Potassium (mmol/L) 4.5 ± 0.5 4.5 ± 0.5 4.5 ± 0.5 0.60
Diuretic 4433 (93.4) 3885 (93.4) 548 (93.7) 0.81
ACEI 2661 (56.1) 2340 (56.3) 321 (54.9) 0.53
ARB 1307 (27.6) 1161 (27.9) 146 (25.0) 0.13
ARNI 508 (10.7) 437 (10.5) 71 (12.1) 0.23
Beta-blocker 4558 (96.1) 4018 (96.6) 540 (92.3) <0.001
≥50% of target dose 2349 (51.5) 2066 (51.4) 283 (52.4) 0.67
Beta-1 selectivea 2779 (58.6) 2427 (58.4) 352 (60.2) 0.42
Non-selectivea 1775 (37.4) 1587 (38.2) 188 (32.1) 0.005
MRAs 3370 (71.0) 2987 (71.8) 383 (65.5) 0.002
Digoxin 887 (18.7) 786 (18.9) 101 (17.3) 0.34
Ivabradine 228 (4.8) 203 (4.9) 25 (4.3) 0.52
PCI 1624 (34.2) 1415 (34.0) 209 (35.7) 0.42
CABG 799 (16.8) 687 (16.5) 112 (19.1) 0.11
CRT 354 (7.5) 305 (7.3) 49 (8.4) 0.37
ICD 953 (20.1) 830 (20.0) 123 (21.0) 0.55
Data are given as mean± standard deviation or median (interquartile range) for continuous measures, and n (%) for categorical measures.
ACEI, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; BMI, body mass index; CABG, coronary artery
bypass graft; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HF, heart failure; HR, heart
rate; ICD, implantable cardioverter-defibrillator; KCCQ-TSS, Kansas City Cardiomyopathy Questionnaire total symptom score; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro
B-type natriuretic peptide; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; SBP, systolic blood pressure.
aFour excluded.
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Clinical outcomes according to chronic
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Primary outcome
Events, n (%) 744 (17.9) 144 (24.6)
Event rate/100 person- years 13.0 (12.1–14.0) 18.9 (16.0–22.2)
HR 1.00 (ref.) 1.44 (1.21–1.72)
<0.001
HR-1 1.00 (ref.) 1.26 (1.05–1.52)
0.014
HR-2 1.00 (ref.) 1.24 (1.03–1.50)
0.023
Worsening HF event
Events, n (%) 456 (11.0) 107 (18.3)
Event rate/100 person-years 8.0 (7.3–8.8) 14.0 (11.6–17.0)
HR 1.00 (ref.) 1.74 (1.41–2.15)
<0.001
HR-1 1.00 (ref.) 1.53 (1.22–1.90)
<0.001
HR-2 1.00 (ref.) 1.51 (1.21–1.89)
<0.001
First HF hospitalization
Events, n (%) 443 (10.7) 106 (18.1)
Event rate/100 person-years 7.7 (7.1–8.5) 13.9 (11.5–16.8)
HR 1.00 (ref.) 1.78 (1.44–2.20)
<0.001
HR-1 1.00 (ref.) 1.58 (1.26–1.97)
<0.001
HR-2 1.00 (ref.) 1.57 (1.25–1.96)
<0.001
Urgent visit for HF
Events, n (%) 30 (0.7) 3 (0.5)
Event rate/100 person-years 0.5 (0.4–0.7) 0.4 (0.1–1.1)
HR 1.00(ref.) 0.75 (0.23–2.45)
0.629
HR-1 1.00 (ref.) 0.63 (0.19–2.12)
0.453
HR-2 1.00 (ref.) 0.54 (0.16–1.86)
0.332
CV death
Events, n (%) 424 (10.2) 76 (13.0)
Event rate/100 person-years 7.1 (6.4–7.8) 9.1 (7.2–11.4)
HR 1.00 (ref.) 1.28 (1.00–1.63)
0.049
HR-1 1.00 (ref.) 1.10 (0.85–1.42)
0.453
HR-2 1.00 (ref.) 1.08 (0.84–1.39)
0.553
Total HF hospitalization/CV death
Events, n 1070 239
Event rate/100 person-years 17.9 (16.8–19.0) 28.8 (25.3–32.7)
RR 1.00 (ref.) 1.59 (1.31–1.93)
<0.001
RR-1 1.00 (ref.) 1.40 (1.15–1.72)
0.001
RR-2 1.00 (ref.) 1.39 (1.14–1.70)
0.001
Non-CV death
Events, n (%) 74 (1.8) 31 (5.3)
Event rate/100 person-years 1.2 (1.0–1.5) 3.7 (2.6–5.2)
HR 1.00 (ref.) 2.99 (1.97–4.56)
<0.001
HR-1 1.00 (ref.) 2.18 (1.38–3.42)
0.001
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All-cause death
Events, n (%) 498 (12.0) 107 (18.3)
Event rate/100 person-years 8.3 (7.6–9.1) 12.7 (10.5–15.4)
HR 1.00 (ref.) 1.53 (1.25–1.89)
<0.001
HR-1 1.00 (ref.) 1.27 (1.02–1.58)
0.031
HR-2 1.00 (ref.) 1.26 (1.01–1.57)
0.041
KCCQ total symptom score (change assessed at 8 months)
Mean change ± SD 4.8 ±18.9 4.1 ±19.8
Differencea −0.67 (−2.52–1.18)
Proportion with ≥5 increase 55.4 49.0
Proportion with ≥5 decrease 28.3 35.0
COPD, chronic obstructive pulmonary disease; CV, cardiovascular; HF, heart failure; HR,
hazard ratio; KCCQ, Kansas City Cardiomyopathy Questionnaire; RR, rate ratio; SD, standard
deviation.
Risk and rate ratios adjusted for randomized treatment and previous HF hospitalization at
baseline (except non-CV and all-cause death) and stratified by diabetes status.
Worsening HF event-HF hospitalization/urgent visit requiring intravenous therapy for HF.
Model 1 adjusted for age, sex, region, systolic blood pressure, history of atrial fibrillation, New
York Heart Association class III/IV, left ventricular ejection fraction, N-terminal pro B-type
natriuretic peptide (log), estimated glomerular filtration rate and smoking status.
Model 2 adjusted the same as Model 1 and for baseline beta-blocker and mineralocorticoid
receptor antagonist prescription.
aIndicates difference in means between patients with COPD and without COPD.
in patients with COPD, compared to those without. Figure 3B
shows health status in patients with COPD, compared with other
common comorbidities. Each of the KCCQ scores was lower
(worse) in patients with COPD than in participants with other
comorbidities.
Effects of dapagliflozin on hospitalization
and mortality outcomes
Table 3 and Figure 1 show the effect of dapagliflozin vs. placebo on
pre-specified outcomes, according to COPD status.
Primary outcome
The effect of dapagliflozin, compared with placebo, on the primary
outcome was consistent in patients with COPD [hazard ratio (HR)
0.67, 95% CI 0.48–0.93] and without COPD (HR 0.76, 95% CI
0.65–0.87; interaction P-value 0.47) (Table 3 and Figure 1).
Worsening heart failure events
The benefit of dapagliflozin, compared with placebo, on worsening
HF events was also consistent in patients with and without COPD
(Table 3 and Figure 1).
Mortality
The effects of dapagliflozin on CV (interaction P-value 0.47) and
all-cause mortality (interaction P-value 0.96) were also consistent
in patients with and without COPD (Table 3 and Figure 1).
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Efficacy of dapagliflozin in DAPA-HF according to chronic obstructive pulmonary disease (COPD) status at baseline. HF, heart
failure.
Effect of dapagliflozin on symptoms
and quality of life assessed using
the Kansas City Cardiomyopathy
Questionnaire
In the pre-specified KCCQ analysis, the improvement in
KCCQ-TSS with dapagliflozin, compared to placebo, was similar
in patients with and without COPD (interaction P-value 0.87) and
the same was true for the exploratory analyses of KCCQ-CSS
and KCCQ-OSS (Table 3 and Figure 4).
Absolute benefits of dapagliflozin
in patients with and without chronic
obstructive pulmonary disease
Applying the overall relative risk reduction (26%) to the placebo
group event rate in those with COPD gave an absolute risk
reduction of 5.9 fewer patients experiencing a primary outcome
per 100 person-years. The equivalent reduction in patients without
COPD was 3.9 fewer patients per 100 person-years.
Applying the overall relative risk reduction (30%) to the


































. absolute risk reduction of 5.3 fewer patients experiencing a
worsening HF event, per 100 person-years of follow-up. The
equivalent reduction in patients without COPD was 2.8 per
100 person-years.
The equivalent figures for death from any cause were 2.3 fewer
per 100 person-years patients with COPD and 1.5 fewer per 100
person-years in patients without COPD.
Pre-specified safety assessments
The proportion of patients stopping study drug for any reason in
the placebo group was higher in patients with COPD, compared to
those without COPD (Table 4). However, the rate of discontinua-
tion was similar between dapagliflozin and placebo in patients with
and without COPD (interaction P-value 0.57).
Adverse events related to volume depletion were reported
in 7.7% of the placebo group and in 8.4% in the dapagliflozin
group in patients with COPD, compared to 6.7% and 7.4%,
respectively, in patients without COPD (Table 4 and Graphical
Abstract). The rate of renal AEs was numerically (but not signifi-
cantly) lower in patients treated with dapagliflozin, compared with
placebo, both in patients with and without COPD (interaction
P-value 0.81).
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Figure 2 Risk of primary outcome and all-cause mortality associated with major comorbidities.
Discussion
In DAPA-HF, patients with COPD were older and more com-
monly men with a history of smoking and atrial fibrillation and
had worse renal function and a higher NT-proBNP level, than
participants without COPD. Patients with COPD were slightly
less likely to be treated with a beta-blocker or MRA and had
more severe functional limitation and impairment of quality of life
than participants without COPD. During follow-up, patients with
COPD experienced higher rates of the primary composite end-
point and key secondary endpoints; fewer had a clinically meaning-
ful improvement (and more deterioration) in symptoms and quality
of life, compared to those without COPD. Efficacy and tolerability
of dapagliflozin were consistent in participants with and without
COPD, with greater absolute risk reductions in hospitalization and
death in COPD patients due to their higher overall event rates.
Mean improvements in symptoms and quality of life were numeri-
cally larger in patients with COPD, compared to those without.
In DAPA-HF, 12.3% of patients had concomitant COPD, very
similar to the frequency reported in most other trials, including
PARADIGM-HF, where prevalence was 12.9%.4–6,19–21 However,
this is likely to be lower than the true prevalence of COPD in
unselected patients with HFrEF for two reasons. First, the inclusion
and exclusion criteria used in trials, including the requirement for
patients to be treated with beta-blocker, unless contraindicated or
not tolerated, likely led to under-enrolment of patients with severe
COPD. Second, use of spirometry would likely have detected
undiagnosed COPD. However, the prevalence of COPD in recent
registry studies has not been much higher. In the European Society
of Cardiology HF Long-Term Registry, the prevalence of COPD
was 14.1%.22 Moreover, 23% of patients in that registry had HF with















































.. in HFpEF than HFrEF.1–3 The proportion of HFrEF patients with
COPD in a US registry was 16.5%.23 In a large Asian registry,
prevalence of COPD was 8.3% (but varied across Asia from 4.7%
to 11%).24
As expected, patients with COPD in DAPA-HF had more
adverse characteristics including older age and more frequent his-
tory of hypertension and, notably, atrial fibrillation. The possibility
that beta-agonists increase the risk of atrial fibrillation has been
raised previously.1
Although prior and current smoking were, as expected, more
common in patients with COPD, coronary heart disease was not
more common. We also found patients with COPD had a higher
mean NT-proBNP level, although only modestly so (and this was
only the case in patients without atrial fibrillation). There was no
clinically relevant difference in LVEF between patients with and
without COPD. The latter findings contrasted strikingly with the
substantially higher proportion of patients with COPD reported
to be in NYHA class III/IV and the significantly lower (worse)
KCCQ-TSS (and other KCCQ scores) in people with COPD
compared to those without. Indeed, all but one of the domains
of KCCQ was worse in patients with COPD compared to most
other comorbidities. Although a similar overall mean decrement
(−8 points) in KCCQ-OSS was reported in the Heart Failure: A
Controlled Trial Investigating Outcomes of Exercise Training trial
(HF-ACTION), we do not know of any other description of the
impact of COPD across domains of quality of life/health status
or any comparison of the impact of COPD compared to other
comorbidities.5
Interestingly, and in contrast to most prior studies, we found
beta-blocker use was high in patients with COPD (92.3%) although
not as high as in patients without COPD (96.6%, P < 0.001). This
finding may indicate that the recommendation in HF guidelines




Figure 3 (A) Individual Kansas City Cardiomyopathy Questionnaire (KCCQ) domain scores at baseline by chronic obstructive pulmonary
disease (COPD) status. (B) Baseline KCCQ scores associated with major comorbidities.
that COPD is not a contraindication to use of a beta-blocker may
have been heeded in this selected clinical trial population.5,19,20,25,26
More surprisingly, however, was the finding that MRA use was also
significantly less common in patients with COPD, despite their
worse functional class. A likely explanation is the higher prevalence
of renal dysfunction among patients with COPD, compared to










. Even after adjusting for differences in demographics, comor-
bidity, key disease-modifying therapy and NT-proBNP, COPD
remained an independent predictor of the primary outcome,
although the impact was greater on worsening HF events that on
CV death. However, there was a clear association between COPD
and death from any cause because of a higher risk of non-CV
death in patients with COPD. The excess risk associated with
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Table 3 Clinical outcomes according to randomized treatment in patients with and without chronic obstructive
pulmonary disease
Without COPD With COPD Interaction









. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Primary outcome
Events (%) 419 (20.1) 325 (15.7) 83 (29.0) 61 (20.4)
Event rate/100 person-years 14.9 (13.5–16.4) 11.2 (10.1–12.5) 22.8 (18.4–28.3) 15.3 (11.9–19.7)
HR 0.76 (0.65–0.87) 0.67 (0.48–0.93) 0.47
Worsening HF event
Events (%) 262 (12.6) 194 (9.4) 64 (22.4) 43 (14.4)
Event rate/100 person-years 9.3 (8.2–10.5) 6.7 (5.8–7.7) 17.6 (13.8–22.5) 10.8 (8.0–14.6)
HR 0.72 (0.60–0.87) 0.61 (0.41–0.90) 0.42
First HF hospitalization
Events (%) 254 (12.2) 189 (9.1) 64 (22.4) 42 (14.1)
Event rate/100 person-years 9.0 (8.0–10.2) 6.5 (5.7–7.5) 17.5 (13.7–22.4) 10.5 (7.8–14.3)
HR 0.73 (0.60–0.88) 0.59 (0.40–0.88) 0.35
CV death
Events (%) 235 (11.3) 189 (9.1) 38 (13.3) 38 (12.7)
Event rate/100 person-years 7.9 (6.9–8.9) 6.3 (5.4–7.2) 9.3 (6.7–12.7) 8.9 (6.5–12.2)
HR 0.80 (0.66–0.97) 0.96 (0.61–1.51) 0.47
Total HF hospitalization/CV death
Events 605 465 137 102
Event rate/100 person-years 20.3 (18.2–22.7) 15.5 (13.7–17.5) 33.8 (27.0–42.9) 24.0 (18.2–32.1)
RR 0.76 (0.65–0.90) 0.71 (0.50–1.03) 0.71
KCCQ total symptom score (change assessed at 8 months)
Mean change± SD 3.4 ±19.2 6.2 ± 18.4 2.4 ± 19.2 5.8 ± 20.2
Between treatment difference 2.73 (1.47–3.99) 3.42 (−0.19–7.04) 0.71
Proportion with ≥5 score increase 51.7 59.2 45.6 52.2
1.16 (1.08–1.24) 1.14 (0.96–1.36) 0.87
Proportion with ≥5 score decrease 31.9 24.6 39.9 30.3
0.84 (0.78–0.90) 0.81 (0.68–0.96) 0.69
All-cause death
Events (%) 272 (13.1) 226 (10.9) 57 (19.9) 50 (16.7)
Event rate/100 person-years 9.1 (8.1–10.2) 7.5 (6.6–8.5) 13.8 (10.7–17.9) 11.7 (8.8–15.4)
HR 0.83 (0.69–0.99) 0.83 (0.57–1.22) 0.96
COPD, chronic obstructive pulmonary disease; CV, cardiovascular; HF, heart failure; HR, hazard ratio; KCCQ, Kansas City Cardiomyopathy Questionnaire; RR, rate ratio; SD,
standard deviation.
Risk and rate ratios adjusted for previous HF hospitalization at baseline (except all-cause death) and stratified by diabetes status.
Worsening HF event-HF hospitalization/urgent visit requiring intravenous therapy for HF.
COPD was striking when compared with other common comor-
bidities, with only chronic kidney disease and diabetes showing a
similar hazard; we are not aware of any comparative analysis of
this type.
These data and our earlier observations on symptoms/quality
of life raise two questions about the interaction between COPD
and HFrEF. The first is why is COPD associated with worse
symptoms and functional status and a higher risk of HF hos-
pitalization? The explanation for the former could simply be
that patients experience the extra impact of two cardiac and
respiratory conditions causing dyspnoea and effort intolerance
(and, potentially, the additional burden of atrial fibrillation). This
does not readily explain higher natriuretic peptide levels in




















.. of COPD on pulmonary artery pressure and right ventricular
function.1,7,28
The benefits of dapagliflozin were consistent in patients with
and without COPD, both for worsening HF events and death. This
finding is especially important because risk was greater in patients
with COPD and, therefore, the absolute risk reduction was larger
in these individuals, than in participants without COPD and also
because this risk reduction persisted despite the competing (nearly
twofold) risk of non-CV death in the COPD group.
Similarly, dapagliflozin was as well tolerated, compared with
placebo, in patients with and without COPD. Collectively, this
preserved efficacy and tolerability is very important, given the risk
faced by patients with COPD and the more limited alternative
options for at least some of these patients.28,29
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Figure 4 Effect of randomized treatment on change in Kansas City Cardiomyopathy Questionnaire (KCCQ) scores from baseline to 8 months
according to chronic obstructive pulmonary disease (COPD) status.
Table 4 Pre-specified safety outcomes and discontinuation according to randomized treatment and chronic
obstructive pulmonary disease statusa
Without COPD With COPD Interaction









. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Any study drug discontinuation
Events (%) 219/2085 (10.5) 214/2074 (10.3) 39/286 (13.6) 35/299 (11.7)
OR 0.98 (0.80–1.20) 0.84 (0.51–1.38) 0.57
AE related study drug discontinuation
Events (%) 95 (4.6) 93 (4.5) 21 (7.4) 18 (6.1)
OR 0.98 (0.73–1.32) 0.80 (0.42–1.54) 0.59
Volume depletion
Events (%) 140 (6.7) 153 (7.4) 22 (7.7) 25 (8.4)
OR 1.11 (0.87–1.41) 1.08 (0.59–1.97) 0.96
Renal AE
Events (%) 137 (6.6) 123 (5.9) 33 (11.6) 30 (10.1)
OR 0.90 (0.70–1.16) 0.84 (0.50–1.42) 0.81
AE, adverse event; COPD, chronic obstructive pulmonary disease; OR, odds ratio.
OR (95% confidence interval) adjusted for baseline diabetes status.
aOnly in safety set except for discontinuation due to any cause.
Limitations
This study has several limitations. The analysis was not
pre-specified and the proportion of patients with COPD
was relatively small, compared to those without. COPD was








. COPD would probably be higher if all patients had performed
spirometry. Participants in this study were selected for a ran-
domized controlled trial and were probably healthier, overall,
than ‘real-world’ patients. Investigators were asked not to include
patients with another condition likely to lead to a life-expectancy of
<2 years, which may have led to exclusion of patients with severe
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COPD. The high rate of use of beta-blockers is also consistent
with the trial participants representing healthier, better-treated,
patients enrolled at sites practicing evidence-based medicine.
Conclusion
In summary, in DAPA-HF, approximately one in eight patients
with HFrEF had concomitant COPD. Participants with COPD
had worse symptoms and functional limitation, compared to
those without, and a higher risk of HF hospitalization and death
from any cause. The relative risk reduction with dapagliflozin on
all pre-specified mortality/morbidity outcomes was the same in
patients with and without COPD (and absolute risk reduction
greater in those with COPD because of their higher baseline risk),
as was the improvement in symptoms. Dapagliflozin was equally
well tolerated, compared with placebo, in patients with and with-
out COPD.
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Additional supporting information may be found online in the
Supporting Information section at the end of the article.
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